PNP Therapeutics, UAB and Southern Research Institute work abolishes otherwise unmanageable human cancers in preclinical rodent studies.
The new 1,600-square-foot Central Alabama High-Field Nuclear Magnetic Resonance Facility provides state-of-the-art sensitivity and resolution for biomedical research and drug discovery.
The University of Alabama System Board of Trustees approved the establishment of the James K. Kirklin, M.D., Endowed Lectureship and other faculty appointments during its Nov. 8 meeting.
Microbiology Professor John Kearney's research in monoclonal antibodies led to treatments for breast cancer, rheumatoid arthritis and more during his 40 years at UAB and earned him selection as the 2013 Distinguished Faculty Lecturer.
Yang’s research focuses on a new class of drug – PARP inhibitors – that interfere with a cancer cell’s ability to repair DNA damage, hastening cell death.
The UAB community came out to support the CPS-3, becoming the largest single site enrollment in the U.S. with 1,209 participants.
In honor of Breast Cancer Awareness Month in October, the BCRFA and other organizations are hosting several local events.
Clinicians will collaborate with local physicians, offering patients updated treatment recommendations and access to cutting-edge research.
Originally built in 1975, the Wallace Tumor Institute is the hub of the Comprehensive Cancer Center’s research and administrative enterprise.